Therapeutics
Therapeutics testing overview
We have access to hundreds of assays to identify and monitor both prescribed and illicit drug use. Our cutting-edge evaluations use advanced and emerging technologies, including liquid chromatography tandem mass spectrometry (LC/MS/MS) and gas chromatography mass spectrometry (GS/MS), to deliver accurate, actionable results that clarify substance use for improved outcomes.
When you partner with Mayo Clinic Laboratories, you extend your network to include some of the world’s leading experts. Mayo Clinic clinicians, laboratorians, and genetic counselors are available to discuss testing options, interpret results, or help with case review and coordination.
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the therapeutics testing capabilities of Mayo Clinic Laboratories, including:
- Addiction rehabilitation
- Alcohol biomarker testing
- Clinical and forensic technology
- Confirmatory testing
- Controlled substance monitoring
- Drug class testing
- Precision therapeutics
- Result interpretation
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.
Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab at Mayo Clinic. Dr. Pritt and Dr. Jannetto discuss the current state of the opioid crisis in the United States, its impact on public health, and the important role of laboratory testing in addiction medicine and pain management patients.
In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
Visit Mayo Clinic Laboratories at booth #2047 to learn about our comprehensive therapeutics test offerings. Developed by board-certified experts in clinical chemistry, molecular, and toxicology testing, our testing is designed to detect and monitor therapeutic and illicit drugs across several relevant specimen types.
Misdiagnosed with acromegaly, a disease marked by too much growth hormone, and plagued by a host of mysterious health problems from unnecessary medications, Kelly DuBois finally found answers after pharmacogenomic testing from Mayo Clinic Laboratories put her on a path toward healing.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.
For Billy Dowell Jr., a competitive golfer, focus, determination, and course correction are essential to excelling at the sport. These skills, along with routine follow-up care and testing, are also important to navigating a life impacted by multiple chronic autoimmune conditions.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Paul Jannetto, Ph.D., associate professor of laboratory medicine and pathology at Mayo Clinic, and discusses how CBD can affect your health, what the medical benefits are, and its impact on urine drugs of abuse testing.
Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested. Clinical toxicology testing is used for routine medical care. Mayo Clinic Laboratories offers a full range of clinical and forensic toxicology testing.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.
Bringing together advanced testing technology, unparalleled expertise, and a patient-focused approach, Mayo Clinic Laboratories’ new high-resolution urine drug testing profile, ADMPU, evaluates for 22 drug classes including alcohol, marijuana, and nicotine, enabling clarity on substance use and precision insights that propel treatment.